SCHEMBL15375307

SCHEMBL15375307

CNC(=O)C(O)c1ccc(Cl)cc1COc1cc(C)ccc1C

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.45
MRGPRX4 Q96LA9 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
LMNA P02545 2/20 0.41
HTT P42858 1/20 0.41
ALDH1A1 P00352 1/20 0.40
SGMS2 Q8NHU3 1/20 0.40
TSHR P16473 2/20 0.40
NPSR1 Q6W5P4 2/20 0.39
MAPK1 P28482 1/20 0.39
MEN1 O00255 1/20 0.38
USP2 O75604 1/20 0.38
KMT2A Q03164 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
POLB P06746 1/20 0.38
CYP2C9 P11712 1/20 0.38
ADRB2 P07550 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15375654 0.91 PTGDR2 (0.45) PTGDR2MRGPRX4SMN1; SMN2LMNAHTT
SCHEMBL15401896 0.88 PTGDR2 (0.46) PTGDR2MRGPRX4SMN1; SMN2LMNAHTT
SCHEMBL15375648 0.88 PTGDR2 (0.48) PTGDR2MRGPRX4SMN1; SMN2LMNAALDH1A1
SCHEMBL15375473 0.87 PTGDR2 (0.43) PTGDR2MRGPRX4SMN1; SMN2LMNAHTT
SCHEMBL15401875 0.86 PTGDR2 (0.49) PTGDR2MRGPRX4SMN1; SMN2LMNAHTT
SCHEMBL3498225 0.85 SMN1; SMN2 (0.44) PTGDR2SMN1; SMN2LMNAHTTALDH1A1
SCHEMBL3498222 0.85 SMN1; SMN2 (0.44) PTGDR2SMN1; SMN2LMNAHTTALDH1A1
SCHEMBL17328308 0.81 PTGDR2 (0.46) PTGDR2MRGPRX4SMN1; SMN2LMNAHTT
SCHEMBL15375389 0.81 PTGDR2 (0.43) PTGDR2MRGPRX4SMN1; SMN2LMNAHTT
SCHEMBL15375528 0.80 LPAR1 (0.42) PTGDR2MRGPRX4LMNAHTTSGMS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2397459-B1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND SUMITOMO CHEMICAL CO (JP) 2015-12-16 EP disclosed
CN-103641731-B The manufacture method of phenylacetyl amine compound SUMITOMO CHEMICAL CO., LTD. (JP) 2015-10-28 CN disclosed
CN-103588657-A Method for producing phenylacetamide compound SUMITOMO CHEMICAL CO 2014-02-19 CN disclosed
EP-2682382-A2 Method for Producing Phenylacetamide Compound Sumitomo Chemical Company, Limited (JP) 2014-01-08 EP disclosed
US-8624062-B2 Method for producing phenylacetamide compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-01-07 US disclosed
EP-2662352-A2 Method for Producing Phenylacetamide Compound Sumitomo Chemical Company, Limited (JP) 2013-11-13 EP disclosed
CN-102348677-A Method for producing phenylacetamide compound SUMITOMO CHEMICAL CO 2012-02-08 CN disclosed
EP-2397459-A1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND Sumitomo Chemical Company, Limited (JP) 2011-12-21 EP disclosed
US-20110295035-A1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110295035-A1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND MRPL21, AADAC, ARSA PTGDR2 938/4885MRGPRX4 1236/4885SMN1; SMN2 4638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.